Provention Bio, Inc. today announced that the resubmitted Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals has been considered a complete, class 2 response to the July 2021 action letter by the U.S. Food and Drug Administration (FDA). The FDA has assigned a user fee…
eTurboNews greinar eru eingöngu fyrir áskrifendur. Áskrift er FRJÁLS.
Áskrifendur skrá sig hér Smelltu hér til að gerast áskrifandi ÓKEYPIS
Áskrifendur skrá sig hér Smelltu hér til að gerast áskrifandi ÓKEYPIS
HVAÐ Á AÐ TAKA ÚR ÞESSARI GREIN:
- today announced that the resubmitted Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals has been considered a complete, class 2 response to the July 2021 action letter by the U.
- Áskrift er ÓKEYPIS.
- eTurboNews greinar eru eingöngu fyrir áskrifendur.
